VYNE Therapeutics Granted Patent for VYN202 BD2-Selective BET Inhibitor

On July 16, 2024, VYNE Therapeutics Inc. (Nasdaq: VYNE), a clinical-stage biopharmaceutical company focused on developing innovative treatments for immuno-inflammatory conditions, announced the granting of GB Patent No. 2621505 by the United Kingdom’s Intellectual Property Office. This patent, which covers the compound in VYNE’s VYN202 program, is valid for 20 years, expiring in June 2042.

David Domzalski, President and CEO of VYNE, emphasized the importance of this patent for the development of VYN202, which the company believes to be the most potent and BD2-selective BET inhibitor currently in development. Domzalski highlighted that securing intellectual property protection is crucial for the company’s growth and they intend to seek similar protections in other jurisdictions as their BET inhibitor pipeline progresses.

The newly issued patent originates from Tay Therapeutics Limited’s Patent Cooperation Treaty (PCT) application No. WO 2023/275542 A1, which was filed in multiple jurisdictions and is exclusively licensed to VYNE. This is the first national patent from these filings to be granted.

VYN202 is an innovative oral small molecule BET inhibitor that exhibits significant class-leading selectivity and potency, particularly in its selectivity for BD2 over BD1. VYNE believes that this selectivity could make VYN202 a highly effective non-biologic treatment option for both acute and chronic management of immuno-inflammatory conditions, where inflammatory signaling activity often causes damage. Unlike VYNE’s pan-BET inhibitor VYN201, VYN202 is structurally distinct and is covered by separate PCT and provisional composition of matter patent applications directed at new chemical entities and their uses.

BET proteins have a crucial role in gene transcription regulation through epigenetic interactions. Recent studies have shown that these proteins are key in regulating B cell and T cell activation and the subsequent inflammatory processes. As epigenetic readers, BET proteins influence the recruitment of transcription factors that are essential for producing several pro-inflammatory cytokines. BET inhibitors, by blocking the transcription of these cytokines, have the potential to treat a wide range of immuno-inflammatory and fibrotic diseases, and they may also have applications in treating myeloproliferative neoplastic disorders.

VYNE’s mission is to enhance patients' lives by developing proprietary, innovative, and differentiated therapies for treating immuno-inflammatory conditions. The company’s InhiBET™ platform includes a locally administered pan-BD BET inhibitor (VYN201) and an orally available BD2-selective BET inhibitor (VYN202), both of which were licensed from Tay Therapeutics Limited.